CL2008001467A1 - Peptidos cilindricos antagonistas de cxcr4 ciclado por lactamas: composicion farmaceutica que los comprenden; y su uso para tratar artitis reumatica, fibrosis pulmonar, infeccion por vih o cancer. - Google Patents

Peptidos cilindricos antagonistas de cxcr4 ciclado por lactamas: composicion farmaceutica que los comprenden; y su uso para tratar artitis reumatica, fibrosis pulmonar, infeccion por vih o cancer.

Info

Publication number
CL2008001467A1
CL2008001467A1 CL2008001467A CL2008001467A CL2008001467A1 CL 2008001467 A1 CL2008001467 A1 CL 2008001467A1 CL 2008001467 A CL2008001467 A CL 2008001467A CL 2008001467 A CL2008001467 A CL 2008001467A CL 2008001467 A1 CL2008001467 A1 CL 2008001467A1
Authority
CL
Chile
Prior art keywords
lactams
cycled
cancer
pharmaceutical composition
cylcr4
Prior art date
Application number
CL2008001467A
Other languages
English (en)
Spanish (es)
Inventor
David Kohn Wayne
Peng Sheng-Bin
Zeng Yan Lang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008001467(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2008001467A1 publication Critical patent/CL2008001467A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CL2008001467A 2007-05-30 2008-05-20 Peptidos cilindricos antagonistas de cxcr4 ciclado por lactamas: composicion farmaceutica que los comprenden; y su uso para tratar artitis reumatica, fibrosis pulmonar, infeccion por vih o cancer. CL2008001467A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US94099607P 2007-05-31 2007-05-31

Publications (1)

Publication Number Publication Date
CL2008001467A1 true CL2008001467A1 (es) 2008-12-05

Family

ID=39831600

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001467A CL2008001467A1 (es) 2007-05-30 2008-05-20 Peptidos cilindricos antagonistas de cxcr4 ciclado por lactamas: composicion farmaceutica que los comprenden; y su uso para tratar artitis reumatica, fibrosis pulmonar, infeccion por vih o cancer.

Country Status (32)

Country Link
US (3) US7691813B2 (OSRAM)
EP (2) EP2160221B1 (OSRAM)
JP (1) JP5358564B2 (OSRAM)
KR (2) KR101319740B1 (OSRAM)
CN (1) CN101678213B (OSRAM)
AR (1) AR066648A1 (OSRAM)
AT (1) ATE516853T1 (OSRAM)
AU (1) AU2008260326B2 (OSRAM)
BR (1) BRPI0812134A2 (OSRAM)
CA (1) CA2688574C (OSRAM)
CL (1) CL2008001467A1 (OSRAM)
CO (1) CO6241137A2 (OSRAM)
CR (1) CR11105A (OSRAM)
CY (1) CY1111815T1 (OSRAM)
DK (1) DK2160221T3 (OSRAM)
DO (1) DOP2009000270A (OSRAM)
EA (1) EA017716B1 (OSRAM)
GT (1) GT200900304A (OSRAM)
HR (1) HRP20110551T1 (OSRAM)
IL (1) IL201685A (OSRAM)
JO (1) JO2776B1 (OSRAM)
MA (1) MA31666B1 (OSRAM)
MX (1) MX2009012952A (OSRAM)
MY (1) MY149432A (OSRAM)
NZ (1) NZ580849A (OSRAM)
PE (1) PE20090299A1 (OSRAM)
PL (1) PL2160221T3 (OSRAM)
PT (1) PT2160221E (OSRAM)
TN (1) TN2009000496A1 (OSRAM)
TW (1) TWI423987B (OSRAM)
WO (1) WO2008150689A1 (OSRAM)
ZA (1) ZA200908345B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
JPWO2012118124A1 (ja) * 2011-03-01 2014-07-07 国立大学法人京都大学 新規ケモカイン受容体拮抗剤
WO2012168336A1 (en) * 2011-06-07 2012-12-13 Polyphor Ag Beta - hairpin peptidomimetics as cxc4 antagonists
CN104780930A (zh) * 2011-09-30 2015-07-15 程云 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2979991A1 (en) 2014-07-31 2016-02-03 Greif International Holding BV. Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat.
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
CN109922818B (zh) * 2016-09-06 2024-02-20 主线生物科学公司 Cxcr4拮抗剂及使用方法
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
KR20200043970A (ko) * 2017-09-05 2020-04-28 메인라인 바이오사이언스 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
WO2019126796A1 (en) * 2017-12-21 2019-06-27 Mainline Biosciences Llc Composition comprising a therapeutic agent and a cxcr4 selective antagonist and methods for using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
US11639373B2 (en) 2018-09-12 2023-05-02 Technische Universität München Therapeutic and diagnostic agents for cancer
CA3108450A1 (en) 2018-09-12 2020-03-19 Technische Universitat Munchen Cxcr4-targeted diagnostic and therapeutic agents with reduced species selectivity
JP7541532B2 (ja) * 2019-04-18 2024-08-28 プロビンシャル・ヘルス・サービシーズ・オーソリティ 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
EP4097120A4 (en) * 2020-01-26 2024-05-01 Mainline Biosciences (Shanghai) Co., Ltd. ISOTOPE-LABELED CXCR4 SELECTIVELY BINDING PEPTIDE CONJUGATE AND METHODS OF MAKING AND USE THEREOF
WO2022082312A1 (en) * 2020-10-21 2022-04-28 Provincial Health Services Authority Novel cxcr4-targeting compounds
TW202235429A (zh) * 2020-12-25 2022-09-16 日商中外製藥股份有限公司 含ｎ－置換－胺基酸殘基之胜肽化合物的製備方法
CN116615411A (zh) * 2020-12-25 2023-08-18 中外制药株式会社 包含n-取代氨基酸残基的肽化合物的制造方法
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
CN119325480A (zh) * 2022-04-20 2025-01-17 省卫生服务机构 靶向cxcr4的化合物及其制备和使用方法
CN115060901A (zh) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規ｃｘｃｒ４アンタゴニスト
CA2643744A1 (en) * 2006-02-27 2007-08-30 Technische Universitaet Muenchen Cancer imaging and treatment

Also Published As

Publication number Publication date
KR20100003737A (ko) 2010-01-11
HRP20110551T1 (hr) 2011-09-30
CA2688574C (en) 2014-02-18
JP2010529957A (ja) 2010-09-02
PE20090299A1 (es) 2009-03-19
BRPI0812134A2 (pt) 2014-11-18
EA017716B1 (ru) 2013-02-28
KR101319740B1 (ko) 2013-10-17
AU2008260326A1 (en) 2008-12-11
EP2160221A1 (en) 2010-03-10
NZ580849A (en) 2012-03-30
MA31666B1 (fr) 2010-09-01
EP2377579A1 (en) 2011-10-19
JO2776B1 (en) 2014-03-15
WO2008150689A1 (en) 2008-12-11
KR20110134519A (ko) 2011-12-14
ZA200908345B (en) 2011-02-23
AU2008260326B2 (en) 2011-07-21
EP2160221B1 (en) 2011-07-20
TN2009000496A1 (en) 2011-03-31
USRE42274E1 (en) 2011-04-05
TWI423987B (zh) 2014-01-21
IL201685A0 (en) 2010-05-31
JP5358564B2 (ja) 2013-12-04
CN101678213A (zh) 2010-03-24
MY149432A (en) 2013-08-30
CN101678213B (zh) 2013-11-06
GT200900304A (es) 2011-11-09
CR11105A (es) 2010-04-12
AR066648A1 (es) 2009-09-02
HK1141474A1 (en) 2010-11-12
KR101169846B1 (ko) 2012-08-01
PL2160221T3 (pl) 2011-12-30
CY1111815T1 (el) 2015-10-07
DK2160221T3 (da) 2011-09-19
US20100130409A1 (en) 2010-05-27
CO6241137A2 (es) 2011-01-20
DOP2009000270A (es) 2010-01-15
IL201685A (en) 2015-04-30
EA200971129A1 (ru) 2010-04-30
US7691813B2 (en) 2010-04-06
PT2160221E (pt) 2011-09-12
ATE516853T1 (de) 2011-08-15
TW200902556A (en) 2009-01-16
US20080300177A1 (en) 2008-12-04
MX2009012952A (es) 2009-12-11
CA2688574A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
CL2008001467A1 (es) Peptidos cilindricos antagonistas de cxcr4 ciclado por lactamas: composicion farmaceutica que los comprenden; y su uso para tratar artitis reumatica, fibrosis pulmonar, infeccion por vih o cancer.
CL2008000121A1 (es) Fragmentos de anticuerpos anti-peptido alfabeta humano covalentemente unidos a polietilenglicol; composicion farmaceutica que los comprende; y su uso para tratar o prevenir una condicion asociada con la actividad del peptido alfabeta.
BR112013025987A2 (pt) derivados de pirimidina para o tratamento de infecções virais
CL2013001339A1 (es) Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2015000942A1 (es) Compuestos de benceno sustituido.
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2008002893A1 (es) Compuestos derivados de n-fenil-(piridin-3-il) acetamida sustituidas; composicion farmaceutica; procedimiento de preparacion; y su uso para prevenir o tratar el cancer.
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
BRPI0810064B8 (pt) compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos
CL2012000238A1 (es) Polipéptido del factor ix; secuencia de adn que lo codifica; célula huésped eucariota; procedimiento de producción; conjugado; composición que lo comprende; y su uso para el tratamiento de la hemofilia b.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2007001488A1 (es) Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina.
CL2008003265A1 (es) Compuestos derivados de heterociclos nitrogenados, supresores de la produccion de colageno; composicion farmaceutica que comprende dichos compuestos; y su uso para prevenir y/o tratar la fibrosis y/o los tumores.
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
CL2011001128A1 (es) Molecula de acido ribonucleico de doble cadena capaz de inhibir la expresion del gen del factor vii; secuencia de acido nucleico que codifica una cadena sentido y/o una cadena antisentido que estan comprendidas en dicha molecula de acido ribonucleico; composicion farmaceutica y su uso para tratar enfermedades tromboembolicas.
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal